GSK plc (GLAXF) stock
GLAXFOTCPharmaceutical PreparationsAlso trades as GSK
Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30
$24.74+0.30 (+1.21%)
Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –
GSK gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was £23.65B, up 5.9% from the year before. Over ten years it grew 4.6% a year on average. The highest annual figure on record is £23.65B in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | £23.65B | +5.9% |
| FY2024 | Dec 31, 2024 | £22.33B | +2.6% |
| FY2023 | Dec 31, 2023 | £21.76B | +10.1% |
| FY2022 | Dec 31, 2022 | £19.77B | +19.6% |
| FY2021 | Dec 31, 2021 | £16.53B | +0.7% |
| FY2020 | Dec 31, 2020 | £16.43B | -25.0% |
| FY2019 | Dec 31, 2019 | £21.89B | +6.4% |
| FY2018 | Dec 31, 2018 | £20.58B | +3.7% |
| FY2017 | Dec 31, 2017 | £19.84B | +6.7% |
| FY2016 | Dec 31, 2016 | £18.60B | +23.4% |
| FY2015 | Dec 31, 2015 | £15.07B | – |